ENXTPA:SPIE
ENXTPA:SPIECommercial Services

SPIE (ENXTPA:SPIE): Assessing Valuation After New Multi‑Year Tesla Energy Storage Agreement

SPIE (ENXTPA:SPIE) just deepened its relationship with Tesla through a multi year European framework agreement for battery energy storage projects, a strategic move that plugs SPIE directly into the grid scale transition story. See our latest analysis for SPIE. Those moves sit against a strong backdrop, with the share price up sharply this year on the back of the Tesla framework, energy transition acquisitions and an upcoming anti dilutive buyback, signalling building momentum and improving...
ENXTPA:PLX
ENXTPA:PLXDiversified Financial

Is There an Opportunity in Pluxee After Its 29% Share Price Slide in 2025?

If you are wondering whether Pluxee is a beaten down opportunity or a value trap at its current price, this is a good place to unpack what the market might be missing. The stock has been choppy lately, up 1.8% over the last week but still down 4.5% over 30 days and roughly 29% lower year to date. This naturally raises questions about whether sentiment has swung too far. Recent coverage has focused on Pluxee's standalone positioning in employee benefits and engagement solutions following its...
ENXTPA:SPIE
ENXTPA:SPIECommercial Services

Should SPIE’s New Tesla Megapack Framework Shape Strategy for (ENXTPA:SPIE) Energy Transition Investors?

SPIE recently announced that it has signed a renewable three‑year European framework agreement with Tesla to deliver Megapack-based battery energy storage system projects across its specialist subsidiaries, covering existing and potential work in France, Belgium, the Netherlands, Poland and Germany. This deal not only deepens SPIE’s role in the energy transition by integrating large-scale storage into power grids, it also standardises project execution and legal terms across Europe,...
ENXTPA:BB
ENXTPA:BBCommercial Services

Will Exiting Rocketbook and Tattoo Brands Refocus Société BIC's (ENXTPA:BB) Narrative on Core Staples?

In December 2025, Société BIC said it would discontinue Rocketbook and its Skin Creative tattoo businesses Inkbox and Tattly, winding down their operations by the first quarter of 2026 after reviewing their performance against group ambitions. This exit from digital writing and tattoo products marks a clear refocus on BIC’s core categories and a tightening of its portfolio discipline. We’ll now examine how BIC’s decision to exit Rocketbook and Skin Creative-tattoo activities reshapes its...
ENXTPA:STMPA
ENXTPA:STMPASemiconductor

Did New €1 Billion EIB Credit Line Just Shift STMicroelectronics' (ENXTPA:STMPA) Investment Narrative?

Earlier this month, STMicroelectronics and the European Investment Bank agreed a €500 million financing tranche as part of a €1 billion credit line to support high-volume semiconductor manufacturing and R&D across key sites in Italy and France. This ninth financing agreement between the two parties, bringing total EIB support to about €4.20 billion, underlines how STMicroelectronics sits at the center of Europe’s push for semiconductor competitiveness and strategic autonomy, particularly...
ENXTPA:SU
ENXTPA:SUElectrical

Has Schneider Electric’s Strong Multi Year Run Left Much Upside for 2025?

If you are wondering whether Schneider Electric is still a smart buy at today’s price, or if most of the upside has already been captured, you are not alone. This article will walk through what the current market is really pricing in. Despite a strong multi year run, with the stock up roughly 121% over five years and almost 90% over three, the more recent picture has flattened out, with the share price roughly flat over 7 days and slightly negative over the last month and year to...
ENXTPA:FDJU
ENXTPA:FDJUHospitality

FDJ United (ENXTPA:FDJU) Valuation Check After Sharp Share Price Slide Despite Rising Earnings

FDJ United (ENXTPA:FDJU) has quietly slipped this year, with the stock down sharply over the past 3 months and year, even as revenue and net income keep grinding higher in the background. See our latest analysis for FDJ United. That slide has come despite the company completing its rebrand to FDJ United and continuing to post steady top line and earnings growth. The year to date share price return of negative 38.09 percent has dragged longer term total shareholder returns lower and is...
ENXTPA:BVI
ENXTPA:BVIProfessional Services

Assessing Bureau Veritas After Recent ESG Expansion and Share Price Weakness in 2025

Wondering if Bureau Veritas is quietly turning into a value opportunity, or if the recent share price drift is a warning sign? This article will walk you through what the numbers really say. The stock has slipped recently, down about 3.0% over the last week, 8.3% over the last month, and 10.6% year to date, but longer term holders are still sitting on gains of 15.4% over three years and 30.8% over five years. Recent headlines have focused on Bureau Veritas expanding its role in...
ENXTPA:SOP
ENXTPA:SOPIT

Sopra Steria Group (ENXTPA:SOP) Is Up 7.5% After Naming Rajesh Krishnamurthy Future CEO

Sopra Steria announced that its board has appointed Rajesh Krishnamurthy as Group Chief Executive Officer, effective February 2, 2026, bringing three decades of international technology, consulting and transformation experience across Europe, Asia and the Americas. His track record in scaling Infosys and transforming Expleo, including shifting toward digital engineering and AI-enabled services, aligns closely with Sopra Steria’s ambitions in high-value, technology-led offerings. We’ll now...
ENXTPA:MEDCL
ENXTPA:MEDCLPharmaceuticals

MedinCell (ENXTPA:MEDCL) Is Up 12.6% After Strong H1 Results And Teva’s FDA Filing - What's Changed

In the past week, MedinCell reported stronger-than-expected H1 2026 earnings while partner Teva submitted a New Drug Application to the FDA for their jointly developed olanzapine long-acting injectable for schizophrenia, alongside progress on multiple late-stage and partnered programs. The combination of UZEDY’s performance, the FDA filing for olanzapine LAI, and new backing for pipeline assets such as the AbbVie and Gates Foundation-supported programs signals a broadening of MedinCell’s...
ENXTPA:ML
ENXTPA:MLAuto Components

Is Michelin Turning into a Value Opportunity After Recent Specialty and Premium Segment Expansion?

Investors may be wondering whether Compagnie Générale des Établissements Michelin Société en commandite par actions is quietly turning into a value opportunity, or if the market already reflects its true worth. The share price is down 0.3% over the last week, 3.4% over the past month and 13.3% year to date. However, it is still up 18.9% over three years and 22.2% over five years, which suggests a mix of recent pessimism and longer term resilience. Recent headlines have focused on Michelin's...
ENXTPA:ERF
ENXTPA:ERFLife Sciences

How Eurofins’ Major Vietnam Lab Expansion Will Impact Eurofins Scientific (ENXTPA:ERF) Investors

Eurofins Consumer Product Testing Vietnam has completed a major expansion, relocating to a purpose-built 7,000 sq. m laboratory in Ho Chi Minh City that offers more than two and a half times the floor space of its previous site. This enlarged facility underscores Eurofins’ commitment to supporting Vietnam’s growing role in global manufacturing supply chains, enhancing its ability to serve international brands, retailers, and manufacturers with broader testing capacity. Next, we’ll explore...
ENXTPA:CA
ENXTPA:CAConsumer Retailing

Carrefour (ENXTPA:CA): Assessing Valuation After New Retail Media Partnership With JCDecaux and Unlimitail

Carrefour (ENXTPA:CA) just expanded its retail media push, signing a strategic deal with JCDecaux, Carmila, and Unlimitail to build indoor and outdoor digital advertising across its shopping centres in France and Spain. See our latest analysis for Carrefour. That push into retail media comes as momentum has quietly improved, with a roughly 10.9% 3 month share price return and a 5.2% one year total shareholder return suggesting sentiment is slowly rebuilding around Carrefour. If Carrefour’s...
ENXTPA:MEDCL
ENXTPA:MEDCLPharmaceuticals

MedinCell (ENXTPA:MEDCL): Assessing Valuation After Teva’s FDA Filing for Olanzapine Long-Acting Injectable

MedinCell (ENXTPA:MEDCL) has been in focus after partner Teva filed a New Drug Application with the U.S. FDA for its olanzapine long acting injectable, which is built on MedinCell’s BEPO technology. See our latest analysis for MedinCell. The latest regulatory milestone appears to have reignited interest in MedinCell, with the 1 day share price return of 3.85 percent and a 90 day share price return of 41.39 percent contributing to a robust 1 year total shareholder return of 77.19 percent. This...
ENXTPA:ARG
ENXTPA:ARGIndustrial REITs

Energy‑Efficient Logistics Expansion Might Change The Case For Investing In Argan (ENXTPA:ARG)

In recent months, ARGAN announced a new lease with JUNG LOGISTIQUE for a 30,000 sq.m AutOnom® logistics facility in Tournan-en-Brie and confirmed with DECATHLON the modernization of heating systems across more than 170,000 sq.m of logistics space using next-generation heat pumps. These projects underline ARGAN’s focus on pairing logistics expansion with concrete energy-efficiency upgrades, enhancing the resilience and decarbonization profile of its tenant portfolio. We’ll now examine how...
ENXTPA:ERF
ENXTPA:ERFLife Sciences

Is Eurofins Scientific Fairly Priced After Portfolio Streamlining and 2025 Share Price Rebound?

If you have been wondering whether Eurofins Scientific is still a quality stock at a fair price, you are not alone, as many investors are trying to figure out if the current share price matches its long term potential. Despite a choppy few weeks, with the share price down 4.4% over the last 7 days and 2.6% over the last month, Eurofins is still up 16.3% year to date and 20.2% over the past year. This hints that the market may be warming back up to its story after a tougher 3 and 5 year...